Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma - diagnostic and therapeutic dilemma

Acta Oncol. 2022 Sep;61(9):1126-1131. doi: 10.1080/0284186X.2022.2083921. Epub 2022 Jun 6.

Authors

Alicja Sadowska-Klasa¹, Mary Abba², Justyna Gajkowska-Kulik³, Jan Maciej Zaucha¹

Affiliations

¹ Department of Hematology and Transplantology, Medical University of Gdańsk, Gdansk, Poland.
² Medical University of Gdańsk, Gdansk, Poland.
³ Department of Hematology and Bone Marrow Transplantation, SSM Nicolaus Copernicus, Toruń, Poland.

PMID: 35668607
DOI: 10.1080/0284186X.2022.2083921

No abstract available

Publication types

Letter

MeSH terms

Humans
Lenalidomide / adverse effects
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Lenalidomide